DBV Technologies S.A. (LON: 0QAJ)

Market Cap	76.49M
Revenue (ttm)	9.34M
Net Income (ttm)	-76.17M
Shares Out	n/a
EPS (ttm)	-0.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,056
Average Volume	32,964
Open	0.910
Previous Close	0.908
Day's Range	0.870 - 0.911
52-Week Range	0.419 - 1.534
Beta	0.86
RSI	58.33
Earnings Date	Mar 5, 2025

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respirato...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 105
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QAJ

Financial Performance

In 2023, DBV Technologies's revenue was $15.73 million, an increase of 224.69% compared to the previous year's $4.84 million. Losses were -$72.73 million, -24.46% less than in 2022.

Financial numbers in USD